New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareProstamax vs Palmitoyl Tetrapeptide-7

Prostamax vs Palmitoyl Tetrapeptide-7

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Prostamax
Skin & Cosmetic
Palmitoyl Tetrapeptide-7
Summary
Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
Palmitoyl Tetrapeptide-7 (Rigin) is a cosmetic peptide consisting of palmitic acid linked to the tetrapeptide sequence GQPR (Gly-Gln-Pro-Arg). It was designed to mimic the biological activity of the IgG immunoglobulin C-terminus, which downregulates the production of interleukin-6 (IL-6), a key driver of skin aging and inflammation.
Half-Life
Short (minutes); sustained gene-regulatory effects
Topical penetration-dependent; effects last hours to days
Admin Route
SubQ, Oral
Topical
Research
Typical Dose
10 mg per day
2-5 ppm concentration in formulation
Frequency
Daily for 10–30 days
Twice daily
Key Benefits
  • Supports normalization of prostate tissue architecture
  • May reduce prostate enlargement associated with BPH
  • Anti-inflammatory effects on prostatic tissue
  • Reduces prostate cell apoptosis from oxidative stress
  • Potential support in chronic prostatitis
  • Anti-aging effects on prostate glandular tissue
  • Complementary to conventional BPH therapies
  • Reduces IL-6 inflammatory cytokine in skin
  • Prevents 'inflammaging' of the skin
  • Inhibits MMP collagen-degrading enzymes
  • Synergistic with Matrixyl for anti-aging
  • Clinically tested for wrinkle and skin texture improvement
  • Well-tolerated topically
Side Effects
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse urological events reported at standard doses
  • Contact sensitization (rare)
  • Well-tolerated at standard concentrations
Stacks With